Here are relevant reports on : rna-therapeutics-market
-
Global Nanomedical Devices and Therapeutics Market (2011-2016)
Nanomedicine, an application of nanotechnology in medical science, is an evolving market. It represents an important segment of nanotechnology which will significantly change the course of treating life threatening diseases. This, unlike other treatment options, is significantly expected to enhance efficacy and minimize overall adversities. Toxicity and environmental impact of nanoscale materials are the major problems nanomedicine. Research and development in nanomedicine is expected to offer a pool of novel products which will improve the health of patients. The robust product pipeline for nanobiomaterials poses a health picture of the market creates significant growth opportunities. However these will have to go through stringent testing protocols before commercialization.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Prostate Cancer Therapeutics Market (2010-2020) (Opportunity Analysis, Pipeline Assessment and Global Market Forecast)
Prostate cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer-related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost.
- Published: November 2011
- Price: $ 4950
- TOC Available:
-
Lung Cancer Therapeutics Market (NSCLC & SCLC) - 2010-2020 (Pipeline Assessment and Market Forecast) in G7 countries
Lung cancer is responsible for most of the deaths (due to cancer) across the globe. With just one drug slated to be launched by 2014 – Talactoferrin by Agennix AG, for patients with advanced lung cancer; having failed both chemotherapy and treatments with epidermal growth factor receptor (EFGR) - Tyrosine kinase inhibitor (TKI). Lung cancer is still an area with high unmet need for early diagnosis and limited treatment options in the advanced stages of lung cancer.
- Published: November 2011
- Price: $ 4950
- TOC Available:
-
Acute Myeloid Leukemia Therapeutics Market in G8 Countries (2010 - 2020)
Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age. Incidence rate of acute myeloid leukemia is high in men and women over 50 years. The acute myeloid leukemia market is segmented into two types; namely childhood acute myeloid leukemia and adulthood acute myeloid leukemia. The market was dominated by AVD regimen in 2010. However, in 2020, the market is expected to be dominated by AVD regimen, Cyatarabine, and Quizartinib drug.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Molecular Weight Marker Market by Products (DNA, RNA, Protein Ladders), Type (Prestained, Specialty), Application (PCR, Western Blotting, Gel Extraction), & End User (Academic Institutes, Pharmaceutical Companies, CRO) - Global Forecast to 2019
The global molecular weight marker market was valued at $265.36 million in 2014 and is poised to grow at a CAGR of 12.23 % between 2014 and 2019, to reach $472.47 million in 2019. Increased research and development spending by biotechnology and pharmaceutical companies, increasing public funding for life science research, and new innovations in genomics and proteomics research will drive the growth of the molecular weight markers market.
- Published: February 2015
- Price: $ 4950
- TOC Available:
-
Electrophoresis Reagents Market by Product (Dyes (EtBr & SYBR) Gels (Polyacrylamide, Starch, & Agarose) Buffer (TBE & TAE)) by Application (Protein Analysis, DNA & RNA Analysis) by Technique (Gel & Capillary Electrophoresis) - Global Forecast to 2020
The global electrophoresis reagents market is projected to grow at a CAGR of 5.4%. The electrophoresis reagents market witnessed substantial growth and rapid technological advancements in the past few years, which had a positive impact on the overall growth of the market. The advancements have allowed the electrophoresis technique to be used in many new applications.
- Published: February 2016
- Price: $ 4950
- TOC Available:
-
Germany Next Generation Sequencing Market by Product (Reagents, Kits, Platforms) Service (CHIP Sequencing, Whole Genome, Methyl, RNA Sequencing), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Application - Forecast to 2031
The Germany Next Generation Sequencing market, valued at USD 0.85 billion in 2025, stood at USD 0.93 billion in 2026 and is projected to advance at a resilient CAGR of 16.0% from 2026 to 2031, culminating in a forecasted valuation of USD 1.96 billion by the end of the period. Next-generation sequencing refers to high-throughput DNA sequencing technologies that are not based on Sanger sequencing.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
UK Next-generation Sequencing Market by Product (Reagents, Kits, Platforms), Service (CHIP Sequencing, Whole Genome, Methyl, RNA Sequencing), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Application, Competition - Forecast to 2031
The UK next-generation sequencing market, valued at USD 0.73 billion in 2025, stood at USD 0.80 billion in 2026 and is projected to advance at a resilient CAGR of 14.8% from 2026 to 2031, culminating in a forecasted valuation of USD 1.59 billion by the end of the period. The report profiles key players such as Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Oxford Nanopore Technologies plc. (UK), QIAGEN (Netherlands), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), PacBio (US), and Eurofins Scientific (Luxembourg).
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
France Next Generation Sequencing Market by Product (Reagents, Kits, Platforms), Service (CHIP Sequencing, Whole Genome, Methyl, RNA Sequencing), Technology (SBS, Nanopore) Workflow (Sequencing, Data Analysis), Application, Competition - Forecast to 2031
The France Next Generation Sequencing market, valued at USD 0.54 billion in 2025, stood at USD 0.59 billion in 2026 and is projected to advance at a resilient CAGR of 14.2% from 2026 to 2031, culminating in a forecasted valuation of USD 1.14 billion by the end of the period. Next-generation sequencing refers to non-Sanger-based, high-throughput DNA sequencing technologies. NGS is fundamentally based on sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Ligase Enzymes Market by Type (DNA, RNA), Source (Viral, Bacterial, Eukaryotic), Grade (RUO, GMP, Diagnostic), Molecular Biology Workflow (Cloning, Sequencing, Synthetic Biology), Application (Research, Diagnostic, Therapeutic) - Global Forecast 2030
The global ligase enzymes market, valued at US$0.25 billion in 2024, stood at US$0.26 billion in 2025 and is projected to advance at a resilient CAGR of 6.8% from 2025 to 2030, culminating in a forecasted valuation of US$0.36 billion by the end of the period. The ligase enzymes market is growing due to the rising demand for molecular diagnostics, the increasing adoption of next-generation sequencing (NGS), expanding applications in synthetic biology, and continuous advancements in enzyme engineering.
- Published: September 2025
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
